Sökning: "dosing individualisation"
Visar resultat 1 - 5 av 6 avhandlingar innehållade orden dosing individualisation.
1. Estimation of Dosing Strategies for Individualisation
Sammanfattning : To increase the proportion of patients with successful drug treatment, dose individualisation on the basis of one or several patient characteristics, a priori individualisation, and/or on the basis of feedback observations from the patient following an initial dose, a posteriori individualisation, is an option. Efficient tools in optimising individualised dosing strategies are population models describing pharmacokinetics (PK) and the relation between pharmacokinetics and pharmacodynamics (PK/PD). LÄS MER
2. Using Pharmacokinetic and Pharmacodynamic Principles to Evaluate Individualisation of Antibiotic Dosing – Emphasis on Cefuroxime
Sammanfattning : Cefuroxime is a renally eliminated antibiotic used against a variety of different bacterial infections. The pharmacokinetics (PK) for cefuroxime was studied in 97 hospitalized patients using population analysis. To be able to measure cefuroxime in human serum a new sensitive analytical method was developed using mass spectrometry detection. LÄS MER
3. Pharmacometric Models for Individualisation of Warfarin in Adults and Children
Sammanfattning : Warfarin is one of the most widely used anticoagulants. Therapy is complicated by warfarin’s narrow therapeutic range and pronounced variability in individual dose requirements. Although warfarin therapy is uncommon in children, it is crucial for children with certain congenital or acquired heart diseases. LÄS MER
4. Pharmacokinetics and Pharmacodynamics of Anti-Cancer Regimens : Emphasis on Busulphan and the Combination Therapies Epirubicin-Docetaxel and Fluorouracil-Epirubicin-Cyclophosphamide
Sammanfattning : Although the main reason for the lack of distinct dose-response and -toxicity relationships for anti-cancer agents is due to variability in pharmacodynamics, variability in pharmacokinetics may also contribute. Hence, not only describing and quantifying the relationship between pharmacokinetics and dose-limiting toxicities, but characterising the pharmacokinetics and its associated variability are of obvious importance in the process of developing dosing strategies for anti-cancer regimens. LÄS MER
5. Dose Adaptation Based on Pharmacometric Models
Sammanfattning : Many drugs exhibit major variability in both pharmacokinetic (PK) and pharmacodynamic (PD) parameters that prevents the use of the same dose for all patients. Variability can occur both between patients (IIV) as well as within patients over the course of time (IOV). LÄS MER
